Centogene N.V. together with Evotec SE have discovered a new small molecule which has the potential to treat patients with type 2 and type 3 Gaucher disease, otherwise known as neuronopathic Gaucher disease.   The discovery was the result of the collaborative work under the existing drug discovery partnership.   The Companies have now extended this collaboration for another year, granting Evotec an R&D License for the continued development activities. The amended agreement also provides ...